A PLGA nanofiber microfluidic device for highly efficient isolation and release of different phenotypic circulating tumor cells based on dual aptamers
Autor: | Weipei Zhu, Yue Pan, Renjun Pei, Qing Li, Zeen Wu, Pi Ding, Zhili Wang, Mingchao Hu, Tian Gao |
---|---|
Rok vydání: | 2021 |
Předmět: |
endocrine system diseases
Aptamer Nanofibers Biomedical Engineering Cell Separation 02 engineering and technology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Circulating tumor cell Polylactic Acid-Polyglycolic Acid Copolymer Limit of Detection Cell Line Tumor Lab-On-A-Chip Devices medicine Humans General Materials Science Bovine serum albumin biology Chemistry Cell adhesion molecule Mesenchymal stem cell General Chemistry General Medicine Cadherins Epithelial Cell Adhesion Molecule Neoplastic Cells Circulating 021001 nanoscience & nanotechnology medicine.disease female genital diseases and pregnancy complications PLGA Phenotype 030220 oncology & carcinogenesis Nanofiber biology.protein Cancer research 0210 nano-technology Ovarian cancer |
Zdroj: | Journal of Materials Chemistry B. 9:2212-2220 |
ISSN: | 2050-7518 2050-750X |
Popis: | The isolation of specific and sensitive circulating tumor cells (CTCs) is significant for applying them in cancer diagnosis and monitoring. In this work, dual aptamer-modified poly(lactic-co-glycolic acid) (PLGA) nanofiber-based microfluidic devices were fabricated to achieve the highly efficient capture and specific release of epithelial and mesenchymal CTCs of ovarian cancer. Dual aptamer targeting epithelial cell adhesion molecules (EpCAM) and N-cadherin proteins to improve the capture sensitivity, bovine serum albumin (BSA) to guarantee the capture purity and the nanofibers to increase the capture efficiency via synchronously and effectively capturing the epithelial and mesenchymal CTCs with good capture specificity and sensitivity from blood samples were used. We used the target cells including the ovarian cancer A2780 cells (N-cadherin-high, EpCAM-low) and OVCAR-3 cells (EpCAM-high, N-cadherin-low) to test the devices, which exhibited good capture efficiency (91% for A2780 cells, 89% for OVCAR-3 cells), release efficiency (95% for A2780 cells, 88% for OVCAR-3 cells), and sensitivity for rare cells (92% for A2780 cells, 88% for OVCAR-3 cells). Finally, the clinical blood samples of ovarian cancer patients were detected by the PLGA nanofiber-based microfluidic device, and 1 to 13 CTCs were successfully confirmed to be captured with the help of immunofluorescence staining identification. The results exhibited that the dual aptamer-modified PLGA nanofiber-based microfluidic device used as a tool for CTC capture has the potential for clinical application to guide the diagnosis, treatment, and prognosis of ovarian cancer patients. |
Databáze: | OpenAIRE |
Externí odkaz: |